Welcome to our dedicated page for The Oncology Institute SEC filings (Ticker: TOI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncology Institute’s filings aren’t just long—they blend cancer-care science, Medicare reimbursement math, and complex physician-practice accounting. Finding how payor contracts affect margin, or where executive quality bonuses sit in the proxy, can take hours.
Stock Titan solves that problem. Our AI reads every page the moment a document hits EDGAR and delivers plain-English answers to questions investors actually ask, like “What did TOI disclose about clinic expansion risk in its latest 10-K?” or “How have insiders traded since the last 8-K material event?”
Browse every form—from the oncology institute quarterly earnings report 10-Q filing to the oncology institute insider trading Form 4 transactions—and see:
- AI-powered summaries that translate oncology jargon and reimbursement tables into clear takeaways.
- Real-time alerts for the Oncology Institute Form 4 insider transactions so you can track executive stock moves before the market reacts.
- Side-by-side trend visuals of drug-dispensary gross margin pulled directly from each 10-Q.
- Flagged notes on Stark and Anti-Kickback compliance appearing in every 10-K risk section.
Need rapid context? Click “Explain” beside any paragraph and our engine instantly answers, “How does this affect Medicare Advantage revenue?”—understanding the oncology institute SEC documents with AI has never been simpler.
Whether you’re parsing the oncology institute proxy statement executive compensation, reviewing clinic purchase details in an 8-K, or seeking the oncology institute annual report 10-K simplified, Stock Titan gives you the insight professionals use to make informed decisions without wading through medical or legal fine print.
The Oncology Institute (TOI) reported a third‑party cybersecurity incident affecting an external software provider that is expected to cause a brief, immaterial delay in fee‑for‑service collections. The company said there is no indication from the provider that any patient personal information was compromised, and the investigation is ongoing.
TOI is working with the provider to mitigate impacts and restore normal billing operations. The disclosure was furnished under Regulation FD.
FAQ
What is the current stock price of The Oncology Institute (TOI)?
What is the market cap of The Oncology Institute (TOI)?
